NasdaqGS - Nasdaq Real Time Price USD

AbCellera Biologics Inc. (ABCL)

Compare

2.4000

+0.3300

+(15.94%)

At close: April 11 at 4:00:02 PM EDT

2.3500

-0.05

(-2.08%)

After hours: April 11 at 7:26:33 PM EDT

AbCellera to Participate at Upcoming Investor Conferences in May and June

VANCOUVER, British Columbia, April 08, 2025--AbCellera to Participate at Upcoming Investor Conferences in May and June

Business Wire 3 days ago

ABCL
+15.94%
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

VANCOUVER, British Columbia, April 03, 2025--AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Business Wire 8 days ago

ABCL
+15.94%
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia, March 25, 2025--AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Business Wire 17 days ago

ABCL
+15.94%
Rapid Micro Biosystems And 2 Other Promising Penny Stocks To Consider

As the U.S. stock market shows signs of recovery with the S&P 500 and Nasdaq slightly higher, investors are closely monitoring economic indicators and policy developments. Amid these conditions, penny stocks—though a somewhat outdated term—remain an intriguing investment area for those seeking potential growth opportunities in smaller or newer companies. When supported by strong financial health, these stocks can offer unique value propositions, making them noteworthy considerations for...

Simply Wall St. 17 days ago

TTI

RPID

ABCL
+15.94%
AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

AbCellera Biologics ( NASDAQ:ABCL ) Full Year 2024 Results Key Financial Results Revenue: US$28.8m (down 24% from FY...

Simply Wall St. last month

ABCL
+15.94%
Q4 2024 Abcellera Biologics Inc Earnings Call

Q4 2024 Abcellera Biologics Inc Earnings Call

Thomson Reuters StreetEvents last month

ABCL
+15.94%
AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ...

Despite a net loss increase and revenue decline, AbCellera Biologics Inc (ABCL) focuses on advancing clinical programs and strengthening its financial position.

GuruFocus.com last month

ABCL
+15.94%
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2024.

Motley Fool last month

ABCL
+15.94%
ABBV
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 26.67% and 40.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ABCL
+15.94%
AbCellera Reports Full Year 2024 Business Results

VANCOUVER, British Columbia, February 27, 2025--AbCellera Reports Full Year 2024 Business Results

Business Wire last month

ABCL
+15.94%
US Penny Stocks To Watch In February 2025

As the S&P 500 reaches record highs, major stock indexes in the United States continue to show resilience and growth. In this context, penny stocks—though often seen as relics of a bygone era—remain relevant for investors seeking opportunities in smaller or less-established companies. By focusing on those with strong financials and potential for growth, these stocks can offer value and stability.

Simply Wall St. last month

DSGN

ABCL
+15.94%
NVTS
One AbCellera Biologics Insider Raised Their Stake In The Previous Year

Viewing insider transactions for AbCellera Biologics Inc.'s ( NASDAQ:ABCL ) over the last year, we see that insiders...

Simply Wall St. last month

ABCL
+15.94%
AbCellera to Participate at Upcoming Investor Conferences in March

VANCOUVER, British Columbia, February 11, 2025--AbCellera to Participate at Upcoming Investor Conferences in March

Business Wire last month

ABCL
+15.94%
3 Promising US Penny Stocks With Market Caps Under $900M

As the U.S. stock market continues to rally following President Trump's return to office, investors are closely watching the impact of new policies on various sectors. In this context, penny stocks remain an intriguing area for those looking for potential growth opportunities. Though often associated with speculative trading, these smaller or newer companies can offer significant returns when they possess strong financial fundamentals. We'll highlight three such penny stocks that stand out...

Simply Wall St. 2 months ago

NVTS

ABCL
+15.94%
DSGN
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

VANCOUVER, British Columbia, January 21, 2025--AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Business Wire 2 months ago

ABCL
+15.94%
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29%

Key Insights The considerable ownership by individual investors in AbCellera Biologics indicates that they collectively...

Simply Wall St. 2 months ago

ABCL
+15.94%
AbCellera Biologics Inc. (ABCL): A Bull Case Theory

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc. (ABCL)’s share was trading at $2.94 as of Jan 16th. ABCL’s trailing P/E was 19.92 according to Yahoo Finance. AbCellera is a biotechnology company that specializes in […]

Insider Monkey 2 months ago

ABCL
+15.94%
AbbVie and Simcere Zaiming link to develop trispecific antibody

The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.

Pharmaceutical Technology 2 months ago

ABBV

ABCL
+15.94%
AbCellera expands collaboration with AbbVie

AbCellera (ABCL) announced that it has expanded its existing collaboration with AbbVie (ABBV) to include the discovery of T-cell engagers in oncology. The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for tumor targets. Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and commercialize therapeutic antibodies resulting from

TipRanks 2 months ago

ABBV

ABCL
+15.94%
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

VANCOUVER, British Columbia, January 13, 2025--AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Business Wire 2 months ago

ABCL
+15.94%

Performance Overview

Return	ABCL	S&P 500 (^GSPC)
YTD	-18.09%	-8.81%
1-Year	-45.21%	+3.16%
3-Year	-72.82%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbCellera Biologics Inc. (ABCL)

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Rapid Micro Biosystems And 2 Other Promising Penny Stocks To Consider

AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Q4 2024 Abcellera Biologics Inc Earnings Call

AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ...

AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

AbCellera Reports Full Year 2024 Business Results

US Penny Stocks To Watch In February 2025

One AbCellera Biologics Insider Raised Their Stake In The Previous Year

AbCellera to Participate at Upcoming Investor Conferences in March

3 Promising US Penny Stocks With Market Caps Under $900M

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29%

AbCellera Biologics Inc. (ABCL): A Bull Case Theory

AbbVie and Simcere Zaiming link to develop trispecific antibody

AbCellera expands collaboration with AbbVie

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Performance Overview